List of Excipients in Branded Drug SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE

« Back to Dashboard

Generic Drugs Containing SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE

Company	Ingredient	NDC	Excipient
Novel Laboratories Inc	sodium sulfate, potassium sulfate, magnesium sulfate	40032-700	ANHYDROUS CITRIC ACID
Novel Laboratories Inc	sodium sulfate, potassium sulfate, magnesium sulfate	40032-700	MALIC ACID
Novel Laboratories Inc	sodium sulfate, potassium sulfate, magnesium sulfate	40032-700	SODIUM BENZOATE
Novel Laboratories Inc	sodium sulfate, potassium sulfate, magnesium sulfate	40032-700	SUCRALOSE
Novel Laboratories Inc	sodium sulfate, potassium sulfate, magnesium sulfate	40032-700	WATER
Lupin Pharmaceuticals Inc	sodium sulfate, potassium sulfate, magnesium sulfate	43386-700	ANHYDROUS CITRIC ACID

What are the Most Frequently-Used Excipients in SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
2	MALIC ACID
2	SODIUM BENZOATE
2	SUCRALOSE
2	WATER

Excipient Strategy and Commercial Opportunities for Sodium Sulfate, Potassium Sulfate, and Magnesium Sulfate Bowel Preparations

Last updated: August 26, 2026

The sodium sulfate, potassium sulfate, and magnesium sulfate combination is an established prescription bowel-preparation platform used in oral solution and tablet products. The main commercial opportunity is not discovery of a new active ingredient. It is differentiation through excipient selection, palatability, tablet burden, electrolyte control, manufacturing efficiency, packaging, and intellectual property around formulation and delivery.

The leading reference products are SUPREP Bowel Prep Kit, an oral solution, and SUTAB, an oral tablet. Both contain sulfate salts that induce catharsis by increasing intestinal osmotic load. SUTAB converts the same active combination into a solid dosage form, while SUPREP uses a concentrated liquid diluted with water before administration.[1,2]

What drugs contain sodium sulfate, potassium sulfate, and magnesium sulfate?

The combination is primarily used for colon cleansing before colonoscopy or other gastrointestinal procedures.

Product	Dosage form	Active salts per treatment course	Sponsor or manufacturer	FDA status
SUPREP Bowel Prep Kit	Oral solution concentrate	Sodium sulfate 17.5 g; potassium sulfate 3.13 g; magnesium sulfate 1.6 g	Braintree Laboratories, Inc.	FDA-approved prescription product
SUTAB	Tablets	Sodium sulfate 17.5 g; potassium sulfate 2.28 g; magnesium sulfate 2.2 g, approximately, depending on label presentation	Sebela Pharmaceuticals or affiliated entities	FDA-approved prescription product
Generic sulfate oral solutions	Oral solution	Generally equivalent active-salt combination	Multiple ANDA applicants and manufacturers	Market status depends on FDA approval and commercial launch

SUPREP is administered in two six-ounce doses of concentrate diluted with water, followed by additional water. SUTAB requires two administrations of 12 tablets, each followed by substantial volumes of water.[1,2]

The active ingredients are not interchangeable on a gram-for-gram basis without considering the salt form, molecular weight, osmolality, renal handling, potassium exposure, magnesium exposure, and overall dosing instructions.

How do the active salts work, and why do excipients matter?

The sulfate salts retain water in the intestinal lumen and stimulate bowel evacuation. Excipients determine how reliably the active salts are delivered, dispersed, swallowed, tolerated, and manufactured.

Functional excipient requirements

Formulation requirement	Relevant excipient function	Commercial consequence
Tablet compression	Binder, filler, granulation aid	Controls tablet hardness and production yield
Rapid disintegration	Superdisintegrant, wetting agent	Reduces incomplete dosage release
High salt loading	Flow aid, lubricant, granulation system	Prevents capping, sticking, and weight variation
Taste control	Flavor, sweetener, coating, bitterness modifier	Influences completion of the regimen
Moisture protection	Film coat, desiccant, high-barrier packaging	Protects hygroscopic sulfate salts
Suspension or solution stability	Buffer, chelator, preservative, viscosity modifier	Supports shelf life and dose uniformity
Patient adherence	Coating, flavor system, lower liquid volume	Differentiates products in colonoscopy preparation
Renal and electrolyte safety	Controlled salt concentration and water instructions	Limits clinically relevant electrolyte disturbances

The formulation challenge is unusually demanding because the active salts constitute most of the dose. A conventional tablet may need to deliver more than 20 grams of active salts across a single treatment course. This creates a high tablet count and leaves limited room for excipients.

What excipients are used in sulfate bowel-preparation products?

SUTAB tablet excipients

SUTAB uses a conventional compressed-tablet architecture with inactive ingredients that include microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, povidone, and coating-related materials, according to the FDA-approved labeling.[2]

The formulation logic is straightforward:

• Microcrystalline cellulose provides bulk and compressibility.
• Povidone supports granulation and mechanical strength.
• Croscarmellose sodium promotes tablet breakup after ingestion.
• Colloidal silicon dioxide improves powder flow.
• Magnesium stearate reduces friction during compression and ejection.
• Film-coating materials improve swallowability and protect the tablet surface.

The commercial constraint is tablet mass. A formulation that increases excipient content may improve manufacturability but increase tablet size, patient burden, and packaging volume.

SUPREP oral solution excipients

SUPREP uses a concentrated liquid containing the sulfate salts with inactive ingredients such as purified water, flavoring components, sweeteners, acidifying or buffering agents, and preservatives identified in the FDA label.[1]

Liquid formulations permit better control of tablet burden but create different problems:

• Sulfate-associated bitterness and metallic taste
• Flavor instability over shelf life
• Preservative compatibility
• Container and closure extractables
• Higher shipping weight
• Dilution and storage instructions
• Risk of patient under-dilution or incomplete water consumption

A successful liquid excipient strategy must improve palatability without increasing osmolality, gastrointestinal intolerance, or regulatory complexity.

Which excipient strategies offer the strongest commercial opportunities?

1. Taste masking and flavor-system engineering

Taste is one of the clearest opportunities. Sulfate salts can produce bitter, saline, metallic, or mineral-like sensory characteristics. A successful system may combine:

• High-intensity sweeteners
• Acidulants
• Fruit or citrus flavors
• Bitter blockers
• Saltiness modulators
• Microencapsulated flavors
• Film coatings for tablets
• Separate flavor sachets selected by patients

The most attractive opportunity is a taste system that improves completion without materially changing active release, osmolality, stability, or labeling requirements.

For liquid products, flavor systems must remain stable in concentrated solution. For tablets, coating technology can reduce immediate taste exposure but must not delay disintegration beyond the intended profile.

2. Lower tablet burden

SUTAB requires 24 tablets per complete regimen. A formulation that reduces tablet count could have material commercial value, but active loading limits the achievable reduction.

Potential approaches include:

• Higher-density granulation
• Controlled compression
• Multilayer tablets
• Large-caplet designs
• Alternative solid oral geometries
• Coated mini-tablets packaged in dose-specific pouches
• Effervescent or dispersible dosage forms

The main barrier is swallowability. Larger tablets may reduce count but worsen patient experience. A lower-count product must demonstrate acceptable mechanical strength, disintegration, stability, and human-factor performance.

3. Modified liquid-volume regimens

Liquid sulfate products generally require a relatively small volume of active concentrate but a larger volume of water. A commercial formulation may target a lower total fluid burden through:

• More concentrated active solutions
• Improved dosing instructions
• Unit-dose packaging
• Premeasured dilution containers
• Palatable ready-to-dilute sachets
• Co-packaged electrolyte water
• Patient-specific flavor options

The limiting factor is safety. The product cannot be optimized solely for lower fluid intake because bowel-cleansing efficacy and electrolyte balance depend on the total hydration regimen.

4. Moisture protection and packaging

Sulfate salts can create manufacturing and stability issues when exposed to moisture. Commercially useful packaging innovations include:

• High-barrier blister packs
• Desiccant-integrated bottles
• Unit-dose pouches
• Child-resistant dose packs
• Calendarized two-dose packaging
• Separate packaging for tablets and hydration instructions
• Tamper-evident packaging with improved opening ergonomics

Packaging patents may be more defensible than broad composition claims when the active combination is established. A company could protect a regimen-specific package, dosing sequence, moisture-control structure, or integrated preparation kit.

5. Excipient systems that improve tablet production

High active loading increases the risk of:

• Poor powder flow
• Tablet weight variation
• Capping and lamination
• Punch sticking
• Slow dissolution
• Segregation of salts and excipients
• Compression-force sensitivity

A manufacturer could develop a differentiated granulation platform using a low-moisture binder system, dry granulation, roller compaction, or optimized particle-size control.

The strongest manufacturing opportunity is an excipient and process combination that produces consistent tablets at commercial scale while maintaining a small tablet footprint. Process know-how may be protected through trade secrets, process patents, or both.

What formulations are protected by patents?

The commercially relevant patent targets are usually formulation, process, packaging, and method-of-use claims rather than basic claims to the three sulfate salts.

Likely patent claim categories

Claim category	Potential subject matter	Competitive value
Composition	Specific ratios of sulfate salts and inactive ingredients	Moderate if narrowly drafted
Tablet formulation	High-load tablet with defined disintegration and hardness	High if difficult to reproduce
Taste masking	Coating, flavor, bitterness suppression, or sensory profile	Moderate to high
Liquid formulation	Concentration, pH, preservative, flavor, or stability system	Moderate
Manufacturing	Granulation, compression, drying, and coating process	High if process is difficult to design around
Packaging	Moisture barrier, unit-dose system, or regimen kit	Moderate
Method of use	Split-dose administration, hydration sequence, or patient subgroup	Potentially high but vulnerable to invalidity or design-around
Device or kit	Integrated dosing container, cup, or preparation system	Moderate

The basic active combination has limited exclusivity value because it is already established in approved products. A new entrant should focus on claim scope that links excipient composition to measurable technical results, such as stability, tablet strength, disintegration, palatability, reduced tablet count, or improved preparation completion.

Broad statements that an excipient improves taste or manufacturability may face enablement, written-description, obviousness, or anticipation challenges. Data-backed claims with defined concentration ranges and performance testing are more commercially useful.

When do sulfate bowel-preparation products lose exclusivity?

Regulatory exclusivity and patent exclusivity must be evaluated separately.

SUPREP was approved in 2010. SUTAB was approved in 2020. New clinical investigation exclusivity, if granted, generally protects qualifying clinical data for a limited period and does not create permanent market exclusivity. Patent expiration depends on the specific patent, patent-term adjustment, terminal disclaimers, pediatric extension, and Orange Book listing.[1,2,3]

Product	FDA approval milestone	Regulatory exclusivity issue	Generic-entry pathway
SUPREP	2010	Any original data exclusivity is historical	ANDA, subject to listed patents and certifications
SUTAB	2020	Any three-year exclusivity would be tied to qualifying new clinical investigations	ANDA, with Paragraph IV or other certification
New sulfate formulation	Date-specific	May qualify for three-year exclusivity if statutory criteria are met	ANDA or 505(b)(2), depending on changes

The Orange Book should be reviewed for current patent listings, expiration dates, and exclusivity codes before making a launch or licensing decision.[3] A product may have limited or no current listed patents even though the sponsor retains trade secrets, unlisted foreign rights, process patents, or litigation leverage.

What Paragraph IV challenges and litigation risks exist?

A generic applicant seeking approval before expiration of listed patents may file a Paragraph IV certification asserting that a patent is invalid, unenforceable, or not infringed. The sponsor may then file a patent-infringement action within 45 days, triggering the statutory stay framework under the Hatch-Waxman Act.[4]

For sulfate bowel preparations, likely dispute areas include:

• Whether a generic tablet falls within a high-active-load formulation claim
• Whether excipient ranges are essential or merely routine
• Whether the generic uses the same or an equivalent coating system
• Whether a split-dose method-of-use claim is infringed
• Whether process claims reach the generic's manufacturing route
• Whether listed patents are properly submitted to the Orange Book
• Whether the patent claims survive obviousness challenges

The most credible litigation risk generally comes from narrow formulation and process patents supported by comparative data. Broad method-of-use claims may be more difficult to enforce if the label includes non-infringing language or if the relevant dosing instructions are mandated by safety considerations.

No specific current Paragraph IV litigation or settlement agreement should be assumed from the existence of an approved reference product. FDA approval, Orange Book listing, USPTO records, and federal court dockets must be aligned for a current litigation assessment.[3-5]

What FDA regulatory status applies to excipient innovation?

A new sulfate bowel-preparation product could pursue several pathways.

ANDA pathway

An ANDA is appropriate when the proposed product demonstrates pharmaceutical equivalence and bioequivalence or otherwise satisfies the applicable requirements for a generic version of the reference product. Excipient changes may be possible, but they must not alter safety, effectiveness, dosage-form performance, labeling requirements, or product quality.

505(b)(2) pathway

A 505(b)(2) application may be relevant when the product differs materially from the reference product, such as through:

• A novel dosage form
• A new flavor or delivery system
• A reduced-volume regimen
• A different concentration
• A novel package or administration method
• A new patient population or dosing schedule

A 505(b)(2) applicant may rely partly on FDA's prior findings for an approved product while supporting the change with new data.[6]

Excipient regulatory controls

Excipient selection should be based on:

• FDA Inactive Ingredient Database precedent
• USP-NF monographs
• GRAS or food-use history where relevant
• Compendial grade and impurity controls
• Residual solvent limits
• Elemental impurity risk
• Microbial limits
• Extractables and leachables
• Nitrosamine and other impurity assessments
• Compatibility with high ionic strength

The FDA Inactive Ingredient Database can support precedent analysis but does not eliminate the need to justify concentration, route, dosage form, and patient exposure.[7]

How does SUTAB compare with SUPREP and competing bowel preparations?

Attribute	SUTAB	SUPREP	PEG-based solutions	Lower-volume PEG products
Main dosage form	Tablets	Concentrated liquid	Large-volume liquid	Liquid, often lower-volume
Key differentiation	No active liquid taste; high tablet count	Lower active dosing burden; liquid taste	Established safety and hydration profile	Reduced fluid burden and improved palatability
Main patient barrier	Swallowing 24 tablets	Taste and required water	Large volume	Cost, taste, and regimen complexity
Excipient opportunity	Coating, compression, disintegration, packaging	Flavor, sweetener, preservative, stability	Flavor and electrolyte balance	Flavor, viscosity, and stability
Generic risk	Tablet formulation and process design-around	Solution formulation and label similarity	Mature generic competition	Product-specific patent and regulatory barriers
Commercial positioning	Solid-dose convenience	Concentrated liquid convenience	Familiarity and clinical acceptance	Adherence and volume reduction

SUTAB is strongest where patients prefer to avoid drinking a flavored preparation. SUPREP is strongest where patients prefer a lower tablet burden. PEG-based products remain important comparators because physicians weigh cleansing efficacy, tolerability, hydration, and patient comorbidities rather than dosage form alone.[1,2,8]

Which companies are positioned to challenge the market?

The market includes:

• Sponsors of branded sulfate products
• Generic manufacturers developing ANDA versions
• Contract manufacturers with high-load tablet capability
• Specialty pharmaceutical companies developing bowel-prep products
• Excipient suppliers with taste-masking or coating technologies
• Packaging companies offering moisture-resistant regimen kits
• CDMOs with oral-liquid and high-compression tablet platforms

The most credible challenger does not need a new active ingredient. It needs a product that improves one measurable commercial variable: fewer tablets, lower total fluid volume, better taste, easier packaging, lower cost, or improved manufacturing yield.

What is the revenue exposure and market opportunity?

The revenue opportunity is concentrated in recurring colonoscopy volume. Demand is supported by colorectal cancer screening, surveillance procedures, gastroenterology practice, and hospital outpatient activity. Product switching is driven by prescription coverage, formulary status, physician preference, patient tolerability, and preparation completion.

A differentiated product could monetize through:

1. Premium branded pricing for improved adherence or lower burden.
2. Generic supply contracts with wholesalers and health systems.
3. Private-label products for pharmacy and distributor channels.
4. Licensing of taste-masking or high-load tablet technology.
5. CDMO manufacturing of active-loaded tablets.
6. Co-packaged hydration and dosing systems.
7. International licensing, subject to local registration and salt-form requirements.

Pricing power is likely strongest for products with a clear patient-facing advantage. A formulation that is merely bioequivalent but offers no improvement will face generic-style price pressure.

How strong is the patent estate for a new sulfate formulation?

A new product can have a commercially useful patent estate if it combines several claim layers:

• Composition claims covering defined excipient ratios
• Tablet claims covering active loading and physical properties
• Coating claims covering taste reduction
• Process claims covering granulation and compression
• Packaging claims covering moisture stability
• Method claims covering split dosing and hydration
• Use claims tied to clinically supported patient outcomes

The estate is weaker if it relies only on routine excipients, broad salt combinations, or a conventional liquid formulation. The most defensible strategy is to generate comparative data against SUPREP and SUTAB showing a quantifiable improvement in stability, completion, tablet count, taste, or manufacturing performance.

Geographic protection should be assessed separately in the United States, Europe, Japan, China, Canada, Australia, and major Latin American markets. Patent term, examination practice, Orange Book linkage, and generic litigation mechanisms differ substantially by jurisdiction.

What generic launch scenarios exist?

Scenario 1: Early Paragraph IV launch

A generic applicant challenges listed patents and prevails in litigation or settlement. Launch may occur before all nominal patent expiration dates.

Scenario 2: Paragraph III launch

The applicant accepts listed patents and launches after the latest enforceable patent expiration date.

Scenario 3: Design-around launch

The applicant changes coating, excipient ratios, granulation, packaging, or administration instructions to avoid relevant claims while retaining pharmaceutical equivalence.

Scenario 4: 505(b)(2) differentiated launch

A company introduces a new liquid volume, tablet count, flavor system, or delivery platform supported by additional clinical or human-factors data.

For investors and licensors, design-around risk is particularly important. A narrow patent covering one excipient range may not block a competitor using another binder, coating polymer, or granulation method.

Key Takeaways

• Sodium sulfate, potassium sulfate, and magnesium sulfate are established bowel-preparation actives with both liquid and tablet commercial platforms.
• The highest-value excipient opportunities are taste masking, tablet-size reduction, moisture protection, rapid disintegration, and high-load manufacturability.
• SUTAB creates a solid-dose platform but carries a substantial tablet burden.
• SUPREP reduces active liquid volume but depends on flavor acceptance and correct dilution.
• New broad composition claims are likely less valuable than tightly supported formulation, process, packaging, and method claims.
• FDA Inactive Ingredient Database precedent, USP standards, and 505(b)(2) strategy are central to excipient development.
• Generic competition can arise through Paragraph IV litigation, Paragraph III launch, or formulation design-around.
• A commercially strong product must demonstrate a measurable patient, manufacturing, or cost advantage over SUTAB and SUPREP.

FAQs

Can sodium sulfate, potassium sulfate, and magnesium sulfate be formulated as an effervescent bowel preparation?

Yes. An effervescent system is technically possible, but acid-base chemistry, moisture sensitivity, dose uniformity, gas generation, taste, and stability would require extensive development. Packaging would likely need strong moisture-barrier protection.

Is magnesium sulfate the main safety limitation in this combination?

Magnesium exposure is one relevant concern, particularly in patients with renal impairment. Potassium, sodium, hydration status, age, concomitant medicines, and baseline electrolyte conditions also affect risk. The approved labels contain patient-selection and hydration warnings.[1,2]

Can a new excipient create three-year FDA exclusivity?

Potentially, but only if the product qualifies under the statutory standard for new clinical investigations essential to approval. A routine excipient substitution without qualifying clinical work generally does not create three-year exclusivity.[6]

Are sulfate bowel-preparation tablets suitable for over-the-counter commercialization?

An over-the-counter switch would require FDA review of consumer labeling, self-selection, safety, dosing comprehension, and clinical risk. Prescription approval does not establish OTC eligibility.

Which excipient technology is most attractive for licensing?

A platform that reduces bitterness or tablet burden while preserving rapid disintegration and high active loading is likely to have the broadest licensing value. The technology should be supported by comparative sensory data, stability data, scalable manufacturing, and patent claims that cover multiple excipient alternatives.

References

1. U.S. Food and Drug Administration. (2023). SUPREP Bowel Prep Kit (sodium sulfate, potassium sulfate, and magnesium sulfate) prescribing information. Braintree Laboratories, Inc.

2. U.S. Food and Drug Administration. (2023). SUTAB (sodium sulfate, magnesium sulfate, and potassium chloride) tablets prescribing information. Sebela Pharmaceuticals.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

5. United States Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

6. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). FDA.

7. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

8. U.S. Food and Drug Administration. (2023). Guidance for industry: Size, shape, and other physical attributes of generic tablets and capsules. FDA.